180 Life Sciences Corp. - CMO Resigns, Joins Advisory Board
Ticker: FRMM · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1690080
Sentiment: neutral
Topics: executive-change, personnel, advisory-board
Related Tickers: ATNF
TL;DR
180 Life Sciences CMO out, but stays on as advisor. Filing also includes financials.
AI Summary
On July 22, 2024, 180 Life Sciences Corp. filed an 8-K report detailing the resignation of Dr. Jonathan Roth as Chief Medical Officer, effective July 19, 2024. The company also announced the appointment of Dr. Jonathan Roth to its Scientific Advisory Board. This filing also includes financial statements and exhibits.
Why It Matters
The departure of a Chief Medical Officer can signal strategic shifts or challenges within a life sciences company, while their subsequent appointment to an advisory board may indicate continued, albeit different, involvement.
Risk Assessment
Risk Level: medium — Changes in key executive positions and the addition of financial statements can introduce uncertainty and require closer scrutiny by investors.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- Dr. Jonathan Roth (person) — Chief Medical Officer and Scientific Advisory Board member
- July 22, 2024 (date) — Date of Report
- July 19, 2024 (date) — Effective date of resignation
FAQ
Who has resigned from their executive role at 180 Life Sciences Corp.?
Dr. Jonathan Roth has resigned as Chief Medical Officer.
When was Dr. Jonathan Roth's resignation effective?
Dr. Jonathan Roth's resignation was effective July 19, 2024.
What new role has Dr. Jonathan Roth taken on at 180 Life Sciences Corp.?
Dr. Jonathan Roth has been appointed to the company's Scientific Advisory Board.
What is the exact name of the company filing this report?
The exact name of the registrant is 180 Life Sciences Corp.
What is the filing date of this Current Report on Form 8-K?
The filing date of this Current Report on Form 8-K is July 23, 2024, with the earliest event reported on July 22, 2024.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-07-23 08:00:38
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
Filing Documents
- ea020982001-8k_180lifesci.htm (8-K) — 29KB
- ea020982001ex99-1_180lifesci.htm (EX-99.1) — 16KB
- 0001013762-24-000598.txt ( ) — 266KB
- atnf-20240722.xsd (EX-101.SCH) — 4KB
- atnf-20240722_def.xml (EX-101.DEF) — 26KB
- atnf-20240722_lab.xml (EX-101.LAB) — 36KB
- atnf-20240722_pre.xml (EX-101.PRE) — 25KB
- ea020982001-8k_180lifesci_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On July 23, 2024, 180 Life Sciences Corp. (the " Company ") filed a press release disclosing the fact that it has been provided an additional extension from a Hearing Panel of the Nasdaq Stock Market LLC (" Nasdaq ") to regain compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market to September 30, 2024. A copy of the press release is included herewith as Exhibit 99.1 and the information in the press release is incorporated by reference into this Item 8.01 in its entirety by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated July 23, 2024 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 23, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer